All Studies Meta Analysis Recent:

Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19

Jevalikar et al., Scientific Reports, doi:10.1038/s41598-021-85809-y (date from preprint)

Dec 2020

Post
Facebook

Source PDF All Meta

Vitamin D for COVID-19

8th treatment shown to reduce risk in October 2020

^*, now known with p < 0.00000000001 from 120 studies, recognized in 8 countries.

Lower risk for mortality, ICU admission, hospitalization, progression, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine complementary and synergistic treatments. ^* >10% efficacy in meta analysis with ≥3 clinical studies.

4,100+ studies for 60+ treatments. c19early.org

Prospective study of 410 hospitalized patients in India showing lower mortality and ICU admission with cholecalciferol treatment, although not statistically significant with the small number of cases. The median total dose was 60,000IU.

No significant difference was found for outcomes based on baseline vitamin D deficiency, however this analysis does not appear to account for the deficient patients that were treated with vitamin D.

Cholecalciferol was used in this study. Meta analysis shows that late stage treatment with calcitriol / calcifediol (or paricalcitol, alfacalcidol, etc.) is more effective than cholecalciferol: 65% [41‑79%] lower risk vs. 39% [26‑49%] lower risk. Cholecalciferol requires two hydroxylation steps to become activated - first in the liver to calcifediol, then in the kidney to calcitriol. Calcitriol, paricalcitol, and alfacalcidol are active vitamin D analogs that do not require conversion. This allows them to have more rapid onset of action compared to cholecalciferol. The time delay for cholecalciferol to increase serum calcifediol levels can be 2-3 days, and the delay for converting calcifediol to active calcitriol can be up to 7 days.

This is the 16th of 120 COVID-19 controlled studies for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 248 sextillion).

29 studies are RCTs, which show efficacy with p=0.0000024.

Important missing comments or errors? Let us know.

risk of death, 82.0% lower, RR 0.18, p = 0.12, treatment 1 of 128 (0.8%), control 3 of 69 (4.3%), NNT 28.

risk of ICU admission, 33.7% lower, RR 0.66, p = 0.29, treatment 16 of 128 (12.5%), control 13 of 69 (18.8%), NNT 16.

risk of oxygen therapy, 31.7% lower, RR 0.68, p = 0.06, treatment 38 of 128 (29.7%), control 30 of 69 (43.5%), NNT 7.3.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Jevalikar et al., 28 Dec 2020, prospective, India, peer-reviewed, 8 authors, dosage 60,000IU single dose, median total dose.

This Paper Vitamin D All

Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19

Ganesh Jevalikar, Ambrish Mithal, Anshu Singh, Rutuja Sharma, Khalid J Farooqui, Shama Mahendru, Arun Dewan, Sandeep Budhiraja

Scientific Reports, doi:10.1038/s41598-021-85809-y

Vitamin D deficiency (VDD) owing to its immunomodulatory effects is believed to influence outcomes in COVID-19. We conducted a prospective, observational study of patients, hospitalized with COVID-19. Serum 25-OHD level < 20 ng/mL was considered VDD. Patients were classified as having mild and severe disease on basis of the WHO ordinal scale for clinical improvement (OSCI). Of the 410 patients recruited, patients with VDD (197,48.2%) were significantly younger and had lesser comorbidities. The levels of PTH were significantly higher in the VDD group (63.5 ± 54.4 vs. 47.5 ± 42.9 pg/mL). The proportion of severe cases (13.2% vs.14.6%), mortality (2% vs. 5.2%), oxygen requirement (34.5% vs.43.4%), ICU admission (14.7% vs.19.8%) was not significantly different between patients with or without VDD. There was no significant correlation between serum 25-OHD levels and inflammatory markers studied. Serum parathormone levels correlated with D-dimer (r 0.117, p-0.019), ferritin (r 0.132, p-0.010), and LDH (r 0.124, p-0.018). Amongst VDD patients, 128(64.9%) were treated with oral cholecalciferol (median dose of 60,000 IU). The proportion of severe cases, oxygen, or ICU admission was not significantly different in the treated vs. untreated group. In conclusion, serum 25-OHD levels at admission did not correlate with inflammatory markers, clinical outcomes, or mortality in hospitalized COVID-19 patients. Treatment of VDD with cholecalciferol did not make any difference to the outcomes.

Author contributions G.J. drafted the study protocol, supervised patient enrollment, analyzed data, wrote the first draft of the manuscript, and will be the corresponding author for the manuscript. A.M. conceptualized the study, guided the study protocol, and critically reviewed the manuscript. A.S. supervised collection and reporting of laboratory investigations and contributed to the data collection. R.S., K.J.F., S.M. contributed to the data collection and analysis. K.J.F. reviewed the study protocol. A.D., S.B. critically reviewed the manuscript along with A.M. Competing interests The authors declare no competing interests.

References

Adams, Hewison, Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity, Nat. Clin. Pract. Endocrinol. Metab

Ali, Role of vitamin D in preventing of COVID-19 infection, progression and severity, J. Infect. Public Health

Baktash, Vitamin D status and outcomes for hospitalised older patients with COVID-19, Postgrad. Med. J, doi:10.1136/postgradmedj-2020-138712

Cannell, Epidemic influenza and vitamin D, Epidemiol. Infect

Carpagnano, Vitamin D deficiency as a predictor of poor prognosis in patients with acute respiratory failure due to COVID-19, J. Endocrinol. Invest, doi:10.1007/s40618-020-01370-x

Cereda, Vitamin D 25OH deficiency in COVID-19 patients admitted to a tertiary referral hospital, Clin. Nutr, doi:10.1016/j.clnu.2020.10.055

Guan, Clinical characteristics of Coronavirus disease 2019 in China, N. Engl. J. Med

Hansdottir, Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state, J. Immunol

Hernández, Vitamin D status in hospitalized patients with SARS-CoV-2 infection, J. Clin. Endocrinol. Metab, doi:10.1210/clinem/dgaa733

Holick, Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline, J. Clin. Endocrinol. Metab

Ilie, Stefanescu, Smith, The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality, Aging Clin. Exp. Res, doi:10.1007/s40520-020-01570-8

Jain, Analysis of vitamin D level among asymptomatic and critically ill COVID-19 patients and its correlation with inflammatory markers, Sci. Rep

Karahan, Katkat, Impact of serum 25(OH) vitamin D level on mortality in patients with COVID-19 in Turkey, J. Nutr. Health Aging

Liu, Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response, Science

Maghbooli, Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection, PLoS ONE, doi:10.1371/journal.pone.0239799

Martineau, Forouhi, Vitamin D for COVID-19: A case to answer?, Lancet Diabetes Endocrinol

Martineau, Vitamin D supplementation to prevent acute respiratory tract infections: Systematic review and meta-analysis of individual participant data, BMJ

Mithal, Global vitamin D status and determinants of hypovitaminosis D, Osteoporos. Int

Murai, Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial, JAMA, doi:10.1001/jama.2020.26848

Ohaegbulam, Swalih, Patel, Smith, Perrin, Vitamin D supplementation in COVID-19 patients: A clinical case series, Am J Ther, doi:10.1097/MJT.0000000000001222

Padhi, Suvankar, Panda, Pati, Panda, Lower levels of vitamin D are associated with SARS-CoV-2 infection and mortality in the Indian population: An observational study, Int. Immunopharmacol

Panagiotou, Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity, Clin. Endocrinol, doi:10.1111/cen.14276

Pham, Rahman, Majidi, Waterhouse, Neale, Acute respiratory tract infection and 25-hydroxyvitamin D concentration: A systematic review and meta-analysis, Int. J. Environ. Res. Public Health, doi:10.3390/ijerph16173020

Pizzini, Impact of vitamin D deficiency on COVID-19: A prospective analysis from the CovILD registry, Nutrients, doi:10.3390/nu12092775

Radujkovic, Vitamin D deficiency and outcome of COVID-19 patients, Nutrients, doi:10.3390/nu12092757

Rastogi, Short term, high-dose vitamin D supplementation for COVID-19 disease: A randomised, placebo-controlled, study (SHADE study), Postgraduate Med. J, doi:10.1136/postgradmedj-2020-139065

Rhodes, Subramanian, Laird, Kenny, low population mortality from COVID-19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity, Aliment. Pharmacol. Ther, doi:10.1111/apt.15777

Samaddar, Gadepalli, Nag, Misra, The enigma of low COVID-19 fatality rate in India, Front. Genet

Wu, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan China, JAMA Intern. Med, doi:10.1001/jamainternmed.2020.0994

Xiao, Vitamin D supplementation for the prevention of childhood acute respiratory infections: A systematic review of randomised controlled trials, Br. J. Nutr

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0